Purple Biotech Ltd. (PPBT) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Purple Biotech Ltd. (NASDAQ: PPBT) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.09 (+13.86% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PPBT ranks #171 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PPBT carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KAPA (Kairos Pharma Ltd.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and MTNB (Matinas Biopharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, PPBT leads on earnings multiple (N/A) while KAPA leads on capital efficiency (-35.0% ROIC).
For Purple Biotech Ltd. (PPBT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #171 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, PPBT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.46) or 200D SMA ($3.02) invalidates the momentum regime and cuts Target Base ($1.10) toward Bear Floor ($0.86).
Purple Biotech Ltd. (PPBT) surged +13.86% to $1.09, trading at 2% of its 52-week range ($0.91 – $9.1). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-
Oral presentation: November 20, 2026 at 15:00 CETREHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PPBT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PPBT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Purple Biotech Ltd. (PPBT) ranks #171 by composite RQD confidence (61/100, grade C-) and #1005 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, PPBT leads on earnings valuation at N/A trailing P/E, while KAPA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PPBT
ACTIVE
Purple Biotech Ltd. | C- | 61/100 | — | — | — | +13.86% | $1.8M | Benchmark Subject |
| KAPA Kairos Pharma Ltd. | D- | 37/100 | — | — | -35.0% | +3.25% | $1.8M | /kapa-vs-ppbt → |
| MTNB Matinas Biopharma Holdings Inc. | D- | 35/100 | — | — | -35.0% | -0.52% | $1.9M | /mtnb-vs-ppbt → |
| OGEN Oragenics Inc. | D | 44/100 | — | — | -35.0% | -1.53% | $1.7M | /ogen-vs-ppbt → |
| XRTX XORTX Therapeutics Inc. | D | 46/100 | — | — | — | -1.90% | $1.9M | /xrtx-vs-ppbt → |
Purple Biotech Ltd. (PPBT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Purple Biotech Ltd. (NASDAQ: PPBT) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.09 (+13.86% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PPBT ranks #171 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PPBT carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KAPA (Kairos Pharma Ltd.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and MTNB (Matinas Biopharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, PPBT leads on earnings multiple (N/A) while KAPA leads on capital efficiency (-35.0% ROIC).
For Purple Biotech Ltd. (PPBT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #171 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
PPBT last traded at $1.09 (+13.86% on volume of 33,690 shares), positioning the stock -25.34% below its 50-day simple moving average ($1.46) and -63.91% below its 200-day simple moving average ($3.02). Across its 52-week range of $0.91 to $9.10, PPBT sits at the 2.2% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).
Why PPBT Stock surged +13.86% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).